constantly replenish the supply of potential blockbusters requires a consistent and dedicated approach to drug R&D. However no longer is inhouse research expertise sufficient. 2 Chart 1 Decreased R&D Productivity (source: FDA - PhRMA 2007) Pharma R&D Investments (Billion USD) 120 New medicines Approved by FDA 60 100 50 80 40 60 30 40 20 20 10 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 YEAR 0 To fill this pipeline gap‚ pharmaceutical
Premium Net present value Discounted cash flow Cash flow
* 1. Decay-Fighting Microbes Bacteria living on teeth convert sugar into lactic acid‚ which erodes enamel and causes tooth decay. Florida-based company ONI BioPharma has engineered a new bacterial strain‚ called SMaRT‚ that cannot produce lactic acid—plus‚ it releases an antibiotic that kills the natural decay-causing strain. Dentists will only need to swab SMaRT‚ now in clinical trials‚ onto teeth once to keep them healthy for a lifetime. * 2. Artificial Lymph Nodes Scientists from Japan’s
Premium Prosthesis Coronary artery disease Artificial limb
1) Millenniums Pharmaceuticals strategy basically focused on revolutionizing drug development through the use of new technology during growth phase and making organizational changes during its maturing phase of by making strategic improvements in the organizational structure‚ making alliances‚ outsourcing etc by having vertical integration and moving from upstream to downstream model. In phase 1‚ technology helped the firm leapfrog most other biotechnology firms in the early stage of drug target
Premium Strategic management
Bio Pharma Case Analysis Question 1 How should BioPharma have used its production network in 2009? Should any of the plants have been idled? What is the annual cost of your proposal‚ including import duties? As Landgraf’s objective is to design a more cost-effective network (cost minimization problem subject to various capacity constraints)‚ the following production network in 2009 should have been used by BioPharma: *All numbers below are in millions *Total Transportation Cost=SUMPRODUCT
Premium Costs Total cost Variable cost
Birmingham‚ November 2011 Nico Bacharidis Globally‚ Tenders & Contracts cover more than half of the Gx market‚ and also affect around 14% of the patented pharma market . In Mature markets the share of tenders - both patented and protected – is a bit lower. •Estimated Size1) of Tendered and Contracted Pharma Market ($bn) •27% of total pharma •$210bn 767 160 Tendered Contracted 141 Generics Total Gx Mar ket •Tendered and Contracted Market by Gx and Patented ($bn) 210 •Over 50% of the global
Premium European Union United Kingdom Western Europe
|OBJECTIVE OF THE STUDY |6 | |3 |NEED TO KNOW PHARMA INDUSTRY |7 | |4 |PHARMA INDUSTRY TODAY |7 | |5 |KEY ISSUE FOR PHARMACEUTICAL
Premium Pharmaceutical industry Pharmacology Generic drug
CASE: And Now‚ a Word from Our Sponsor Question 1: Should Byrant Pharma approve Laura’s idea? Why? Why not? Byrant Pharma should approve Laura’s idea for the following reason: A dramatic increase in the sales was the objective since the market would be flooded with generics in a couple of years. Target consumer is elderly people‚ for which morning news is very appropriate. Also Jeanne Alyson was a favourite with that target group. This would gather Seflex more credibility. Though she is being
Premium Target market Promotion and marketing communications Target audience
Biotechnology: Of Ethics and Advancement Thousands of years ago‚ early man‚ like the rest of earth’s fauna and flora‚ was at the mercy of the elements; we relied on nature’s gratitude when it came to finding food and survival. As Charles Darwin would say‚ only the fittest could survive Mother Nature’s test. Eventually‚ however‚ a fully-evolved man turned the tide of the competition; we began to domesticate the once savage beasts we hunted and competed with like wolves and horses turning them
Premium Nature French Revolution Life
finding it viable to increase their operations in the country. The Indian pharmaceutical industry is highly fragmented with about 24‚000 players (330 in the organized sector). The top ten companies make up for more than a third of the MARKET Indian pharma companies have a large chunk of their revenues coming from exports. While some are focusing on the generics MARKET in the US‚ Europe and semi-regulated markets‚ others are turning their attention to custom manufacturing for innovator companies. Biopharmaceuticals
Premium Pharmaceutical industry Generic drug Pharmacology
field of Biotechnology‚ I had a brief understanding but nothing near an in depth understanding of the field. So when I first started looking for a success story‚ I tied my views on successful innovation in the areas that I am familiar with to the biotech field. The major theme that emerged was that successful innovation equals a product that produces quality profits for a company. After further research on the success of innovation‚ you do realize that profits may be the end goal of the company
Premium Roundup Biotechnology Soybean